Overview

Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen

Status:
Completed

Trial end date:
2009-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the efficacy and the safety Larotaxel administered as single agent every 3 weeks to continuous administration of 5-FU every 3 weeks, in patients with advanced pancreatic cancer (non operable in a curative intent, locally recurrent or metastatic) previously treated with gemcitabine based therapy.

Phase:

Phase 3

Details

Lead Sponsor:

Sanofi

Treatments:

Capecitabine
Fluorouracil
Gemcitabine